The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A07 | Antidiarrheals, intestinal antiinflammatory/antiinfective agents | |
| 3 | A07A | Intestinal antiinfectives | |
| 4 | A07AA | Antibiotics | |
| 5 | A07AA12 |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.4 g |
| Active Ingredient | Description | |
|---|---|---|
| Fidaxomicin |
Fidaxomicin is an antibiotic belonging to the macrocyclic class of antibacterials. Fidaxomicin is bactericidal and inhibits RNA synthesis by bacterial RNA polymerase. It interferes with RNA polymerase at a distinct site from that of rifamycins. Fidaxomicin is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| DIFICID Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| DIFICLIR Granules for oral suspension | European Medicines Agency (EU) | MPI, EU: SmPC | |
| DIFLICIR Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
